Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 115

1.

A Laboratory Medicine Best Practices Systematic Review and Meta-analysis of Nucleic Acid Amplification Tests (NAATs) and Algorithms Including NAATs for the Diagnosis of Clostridioides (Clostridium) difficile in Adults.

Kraft CS, Parrott JS, Cornish NE, Rubinstein ML, Weissfeld AS, McNult P, Nachamkin I, Humphries RM, Kirn TJ, Dien Bard J, Lutgring JD, Gullett JC, Bittencourt CE, Benson S, Bobenchik AM, Sautter RL, Baselski V, Atlas MC, Marlowe EM, Miller NS, Fischer M, Richter SS, Gilligan P, Snyder JW.

Clin Microbiol Rev. 2019 May 29;32(3). pii: e00032-18. doi: 10.1128/CMR.00032-18. Print 2019 Jun 19.

2.

New filovirus disease classification and nomenclature.

Kuhn JH, Adachi T, Adhikari NKJ, Arribas JR, Bah IE, Bausch DG, Bhadelia N, Borchert M, Brantsæter AB, Brett-Major DM, Burgess TH, Chertow DS, Chute CG, Cieslak TJ, Colebunders R, Crozier I, Davey RT, de Clerck H, Delgado R, Evans L, Fallah M, Fischer WA 2nd, Fletcher TE, Fowler RA, Grünewald T, Hall A, Hewlett A, Hoepelman AIM, Houlihan CF, Ippolito G, Jacob ST, Jacobs M, Jakob R, Jacquerioz FA, Kaiser L, Kalil AC, Kamara RF, Kapetshi J, Klenk HD, Kobinger G, Kortepeter MG, Kraft CS, Kratz T, Bosa HSK, Lado M, Lamontagne F, Lane HC, Lobel L, Lutwama J, Lyon GM 3rd, Massaquoi MBF, Massaquoi TA, Mehta AK, Makuma VM, Murthy S, Musoke TS, Muyembe-Tamfum JJ, Nakyeyune P, Nanclares C, Nanyunja M, Nsio-Mbeta J, O'Dempsey T, Pawęska JT, Peters CJ, Piot P, Rapp C, Renaud B, Ribner B, Sabeti PC, Schieffelin JS, Slenczka W, Soka MJ, Sprecher A, Strong J, Swanepoel R, Uyeki TM, van Herp M, Vetter P, Wohl DA, Wolf T, Wolz A, Wurie AH, Yoti Z.

Nat Rev Microbiol. 2019 May;17(5):261-263. doi: 10.1038/s41579-019-0187-4. No abstract available.

3.

A Novel Approach to Infectious Disease Preparedness: Incorporating Investigational Therapeutics and Research Objectives into Full-Scale Exercises.

Vasa A, Madad S, Larson L, Kraft CS, Vanairsdale S, Grein JD, Garland J, Butterworth VM, Kratochvil CJ.

Health Secur. 2019 Jan/Feb;17(1):54-61. doi: 10.1089/hs.2018.0100.

PMID:
30779611
4.

The Special Pathogens Research Network: Enabling Research Readiness.

Kraft CS, Kortepeter MG, Gordon B, Sauer LM, Shenoy ES, Eiras DP, Larson L, Garland JA, Mehta AK, Barrett K, Price CS, Croyle C, West LR, Noren B, Kline S, Arguinchona C, Arguinchona H, Grein JD, Connally C, McLellan S, Risi GF, Uyeki TM, Davey RT Jr, Schweinle JE, Schwedhelm MM, Harvey M, Hunt RC, Kratochvil CJ.

Health Secur. 2019 Jan/Feb;17(1):35-45. doi: 10.1089/hs.2018.0106.

PMID:
30779607
5.

Macrophage Activation Marker Soluble CD163 Associated with Fatal and Severe Ebola Virus Disease in Humans1.

McElroy AK, Shrivastava-Ranjan P, Harmon JR, Martines RB, Silva-Flannery L, Flietstra TD, Kraft CS, Mehta AK, Lyon GM, Varkey JB, Ribner BS, Nichol ST, Zaki SR, Spiropoulou CF.

Emerg Infect Dis. 2019 Feb;25(2):290-298. doi: 10.3201/eid2502.181326.

6.

Tuberculosis following PD-1 blockade for cancer immunotherapy.

Barber DL, Sakai S, Kudchadkar RR, Fling SP, Day TA, Vergara JA, Ashkin D, Cheng JH, Lundgren LM, Raabe VN, Kraft CS, Nieva JJ, Cheever MA, Nghiem PT, Sharon E.

Sci Transl Med. 2019 Jan 16;11(475). pii: eaat2702. doi: 10.1126/scitranslmed.aat2702.

PMID:
30651320
7.

The Use of Microbiome Restoration Therapeutics to Eliminate Intestinal Colonization With Multidrug-Resistant Organisms.

Gopalsamy SN, Woodworth MH, Wang T, Carpentieri CT, Mehta N, Friedman-Moraco RJ, Mehta AK, Larsen CP, Kraft CS.

Am J Med Sci. 2018 Nov;356(5):433-440. doi: 10.1016/j.amjms.2018.08.015. Epub 2018 Aug 29.

PMID:
30384952
8.

Designing Studies Acceptable for Abstraction and Inclusion in Evidence-Based Laboratory Practice Guidelines.

Saubolle MA, Weissfeld AS, Kraft CS.

J Clin Microbiol. 2019 Feb 27;57(3). pii: e00842-18. doi: 10.1128/JCM.00842-18. Print 2019 Mar.

9.

Making the invisible visible: Why does design matter for safe doffing of personal protection equipment?

Zimring CM, Matić Z, Wong Sala MF, Mumma JM, Kraft CS, Casanova LM, Erukunuakpor K, Durso FT, Walsh VL, Shah P, Jacob JT, DuBose JR; CDC Prevention Epicenters Program.

Infect Control Hosp Epidemiol. 2018 Nov;39(11):1375-1377. doi: 10.1017/ice.2018.206. Epub 2018 Oct 2. No abstract available.

PMID:
30277187
10.

Determining qualitative effect size ratings using a likelihood ratio scatter matrix in diagnostic test accuracy systematic reviews.

Rubinstein ML, Kraft CS, Parrott JS.

Diagnosis (Berl). 2018 Nov 27;5(4):205-214. doi: 10.1515/dx-2018-0061.

PMID:
30243015
11.

Fecal microbiota transplantation for the treatment of recurrent and severe Clostridium difficile infection in solid organ transplant recipients: A multicenter experience.

Cheng YW, Phelps E, Ganapini V, Khan N, Ouyang F, Xu H, Khanna S, Tariq R, Friedman-Moraco RJ, Woodworth MH, Dhere T, Kraft CS, Kao D, Smith J, Le L, El-Nachef N, Kaur N, Kowsika S, Ehrlich A, Smith M, Safdar N, Misch EA, Allegretti JR, Flynn A, Kassam Z, Sharfuddin A, Vuppalanchi R, Fischer M.

Am J Transplant. 2019 Feb;19(2):501-511. doi: 10.1111/ajt.15058. Epub 2018 Aug 31.

PMID:
30085388
12.

Developing and Assessing the Feasibility of a Home-based Preexposure Prophylaxis Monitoring and Support Program.

Siegler AJ, Mayer KH, Liu AY, Patel RR, Ahlschlager LM, Kraft CS, Fish R, Wiatrek SE, Sullivan PS.

Clin Infect Dis. 2019 Jan 18;68(3):501-504. doi: 10.1093/cid/ciy529.

13.

Design strategies to improve healthcare worker safety in biocontainment units: learning from ebola preparedness.

DuBose JR, Matić Z, Sala MFW, Mumma JM, Kraft CS, Casanova LM, Erukunuakpor K, Durso FT, Walsh VL, Shah P, Zimring CM, Jacob JT; CDC Prevention Epicenters Program.

Infect Control Hosp Epidemiol. 2018 Aug;39(8):961-967. doi: 10.1017/ice.2018.125. Epub 2018 Jun 18.

PMID:
29909821
14.

Evaluation of Performance Characteristics of Panther Fusion Assays for Detection of Respiratory Viruses from Nasopharyngeal and Lower Respiratory Tract Specimens.

Sam SS, Caliendo AM, Ingersoll J, Abdul-Ali D, Hill CE, Kraft CS.

J Clin Microbiol. 2018 Jul 26;56(8). pii: e00787-18. doi: 10.1128/JCM.00787-18. Print 2018 Aug.

15.

Novel PET and Near Infrared Imaging Probes for the Specific Detection of Bacterial Infections Associated With Cardiac Devices.

Takemiya K, Ning X, Seo W, Wang X, Mohammad R, Joseph G, Titterington JS, Kraft CS, Nye JA, Murthy N, Goodman MM, Taylor WR.

JACC Cardiovasc Imaging. 2019 May;12(5):875-886. doi: 10.1016/j.jcmg.2018.02.011. Epub 2018 Apr 18.

PMID:
29680350
16.

Ebola Virus Persistence in Ocular Tissues and Fluids (EVICT) Study: Reverse Transcription-Polymerase Chain Reaction and Cataract Surgery Outcomes of Ebola Survivors in Sierra Leone.

Shantha JG, Mattia JG, Goba A, Barnes KG, Ebrahim FK, Kraft CS, Hayek BR, Hartnett JN, Shaffer JG, Schieffelin JS, Sandi JD, Momoh M, Jalloh S, Grant DS, Dierberg K, Chang J, Mishra S, Chan AK, Fowler R, O'Dempsey T, Kaluma E, Hendricks T, Reiners R, Reiners M, Gess LA, ONeill K, Kamara S, Wurie A, Mansaray M, Acharya NR, Liu WJ, Bavari S, Palacios G, Teshome M, Crozier I, Farmer PE, Uyeki TM, Bausch DG, Garry RF, Vandy MJ, Yeh S.

EBioMedicine. 2018 Apr;30:217-224. doi: 10.1016/j.ebiom.2018.03.020. Epub 2018 Mar 23.

17.

Severe Community-Acquired Pneumonia due to Acinetobacter baumannii in North America: Case Report and Review of the Literature.

Serota DP, Sexton ME, Kraft CS, Palacio F.

Open Forum Infect Dis. 2018 Mar 10;5(3):ofy044. doi: 10.1093/ofid/ofy044. eCollection 2018 Mar.

18.

Long-term stability of CMV DNA in human breast milk.

Sam SS, Ingersoll J, Racsa LD, Caliendo AM, Racsa PN, Igwe D, Abdul-Ali D, Josephson C, Kraft CS.

J Clin Virol. 2018 May;102:39-41. doi: 10.1016/j.jcv.2018.02.014. Epub 2018 Feb 21.

PMID:
29486386
19.

Assessing Viral Transfer During Doffing of Ebola-Level Personal Protective Equipment in a Biocontainment Unit.

Casanova LM, Erukunuakpor K, Kraft CS, Mumma JM, Durso FT, Ferguson AN, Gipson CL, Walsh VL, Zimring C, DuBose J, Jacob JT; Centers for Disease Control and Prevention Epicenters Program, Division of Healthcare Quality Promotion.

Clin Infect Dis. 2018 Mar 5;66(6):945-949. doi: 10.1093/cid/cix956.

PMID:
29471475
20.

Human Factors Risk Analyses of a Doffing Protocol for Ebola-Level Personal Protective Equipment: Mapping Errors to Contamination.

Mumma JM, Durso FT, Ferguson AN, Gipson CL, Casanova L, Erukunuakpor K, Kraft CS, Walsh VL, Zimring C, DuBose J, Jacob JT; Centers for Disease Control and Prevention Epicenters Program, Division of Healthcare Quality Promotion.

Clin Infect Dis. 2018 Mar 5;66(6):950-958. doi: 10.1093/cid/cix957.

PMID:
29471368
21.

New Lineage of Lassa Virus, Togo, 2016.

Whitmer SLM, Strecker T, Cadar D, Dienes HP, Faber K, Patel K, Brown SM, Davis WG, Klena JD, Rollin PE, Schmidt-Chanasit J, Fichet-Calvet E, Noack B, Emmerich P, Rieger T, Wolff S, Fehling SK, Eickmann M, Mengel JP, Schultze T, Hain T, Ampofo W, Bonney K, Aryeequaye JND, Ribner B, Varkey JB, Mehta AK, Lyon GM 3rd, Kann G, De Leuw P, Schuettfort G, Stephan C, Wieland U, Fries JWU, Kochanek M, Kraft CS, Wolf T, Nichol ST, Becker S, Ströher U, Günther S.

Emerg Infect Dis. 2018 Mar;24(3):599-602. doi: 10.3201/eid2403.171905.

22.

Fecal Microbiota Transplant for Refractory Clostridium difficile Infection Interrupts 25-Year History of Recurrent Urinary Tract Infections.

Wang T, Kraft CS, Woodworth MH, Dhere T, Eaton ME.

Open Forum Infect Dis. 2018 Jan 15;5(2):ofy016. doi: 10.1093/ofid/ofy016. eCollection 2018 Feb. No abstract available.

23.

Tacrolimus concentration to dose ratio in solid organ transplant patients treated with fecal microbiota transplantation for recurrent Clostridium difficile infection.

Woodworth MH, Kraft CS, Meredith EJ, Mehta AK, Wang T, Mamo YT, Dhere T, Sitchenko KL, Patzer RE, Friedman-Moraco RJ.

Transpl Infect Dis. 2018 Apr;20(2):e12857. doi: 10.1111/tid.12857. Epub 2018 Mar 13.

24.

Trends in rotavirus from 2001 to 2015 in two paediatric hospitals in Atlanta, Georgia.

Sederdahl BK, Yi J, Jerris RC, Gillespie SE, Westblade LF, Kraft CS, Shane AL, Anderson EJ.

Epidemiol Infect. 2018 Mar;146(4):465-467. doi: 10.1017/S0950268818000183. Epub 2018 Feb 12.

PMID:
29429424
25.

Fecal Microbiota Transplant for Multidrug-Resistant Organism Decolonization Administered During Septic Shock.

Gopalsamy SN, Sherman A, Woodworth MH, Lutgring JD, Kraft CS.

Infect Control Hosp Epidemiol. 2018 Apr;39(4):490-492. doi: 10.1017/ice.2017.300. Epub 2018 Jan 18. No abstract available.

26.

Short Communication: Anatomic Site of Sampling and the Rectal Mucosal Microbiota in HIV Negative Men Who Have Sex with Men Engaging in Condomless Receptive Anal Intercourse.

Pescatore NA, Pollak R, Kraft CS, Mulle JG, Kelley CF.

AIDS Res Hum Retroviruses. 2018 Mar;34(3):277-281. doi: 10.1089/AID.2017.0206. Epub 2018 Feb 7.

27.

Durability and Long-term Clinical Outcomes of Fecal Microbiota Transplant Treatment in Patients With Recurrent Clostridium difficile Infection.

Mamo Y, Woodworth MH, Wang T, Dhere T, Kraft CS.

Clin Infect Dis. 2018 May 17;66(11):1705-1711. doi: 10.1093/cid/cix1097.

28.

Clinical Laboratory Values in Human Ebola Virus Disease Support the Relevance of the Intramuscular Ebola-Kikwit Rhesus Model.

Reisler RB, Kraft CS, Bavari S, Cardile AP.

Clin Infect Dis. 2018 Apr 17;66(9):1479-1480. doi: 10.1093/cid/cix1025. No abstract available.

PMID:
29272400
29.

Performance evaluation of the Aptima HSV-1 and 2 assay for the detection of HSV in cutaneous and mucocutaneous lesion specimens.

Sam SS, Caliendo AM, Ingersoll J, Abdul-Ali D, Kraft CS.

J Clin Virol. 2018 Feb - Mar;99-100:1-4. doi: 10.1016/j.jcv.2017.12.006. Epub 2017 Dec 13.

PMID:
29253834
30.

Reply to Nicastri et al.

Raabe V, O'Neal JP, Drenzek C, Kraft CS.

Clin Infect Dis. 2018 Feb 1;66(4):638-639. doi: 10.1093/cid/cix865. No abstract available.

PMID:
29186318
31.

Ethical Considerations in Microbial Therapeutic Clinical Trials.

Woodworth MH, Sitchenko KL, Carpentieri C, Friedman-Moraco RJ, Wang T, Kraft CS.

New Bioeth. 2017 Nov;23(3):210-218. doi: 10.1080/20502877.2017.1387386. Epub 2017 Oct 17.

32.

The Female Genital Tract Microbiome Is Associated With Vaginal Antiretroviral Drug Concentrations in Human Immunodeficiency Virus-Infected Women on Antiretroviral Therapy.

Donahue Carlson R, Sheth AN, Read TD, Frisch MB, Mehta CC, Martin A, Haaland RE, Patel AS, Pau CP, Kraft CS, Ofotokun I.

J Infect Dis. 2017 Nov 15;216(8):990-999. doi: 10.1093/infdis/jix420.

33.

Favipiravir and Ribavirin Treatment of Epidemiologically Linked Cases of Lassa Fever.

Raabe VN, Kann G, Ribner BS, Morales A, Varkey JB, Mehta AK, Lyon GM, Vanairsdale S, Faber K, Becker S, Eickmann M, Strecker T, Brown S, Patel K, De Leuw P, Schuettfort G, Stephan C, Rabenau H, Klena JD, Rollin PE, McElroy A, Ströher U, Nichol S, Kraft CS, Wolf T; Emory Serious Communicable Diseases Unit.

Clin Infect Dis. 2017 Sep 1;65(5):855-859. doi: 10.1093/cid/cix406.

34.

A Case of Human Lassa Virus Infection With Robust Acute T-Cell Activation and Long-Term Virus-Specific T-Cell Responses.

McElroy AK, Akondy RS, Harmon JR, Ellebedy AH, Cannon D, Klena JD, Sidney J, Sette A, Mehta AK, Kraft CS, Lyon MG, Varkey JB, Ribner BS, Nichol ST, Spiropoulou CF.

J Infect Dis. 2017 Jun 15;215(12):1862-1872. doi: 10.1093/infdis/jix201.

35.

The microbiome: current and future view of an ancient paradigm.

Neish AS, Pacifici R, Mulle JG, Kraft CS, Stephens DS.

Future Microbiol. 2017 Aug;12:831-834. doi: 10.2217/fmb-2017-0083. Epub 2017 Jun 29. No abstract available.

36.

The National Ebola Training and Education Center: Preparing the United States for Ebola and Other Special Pathogens.

Kratochvil CJ, Evans L, Ribner BS, Lowe JJ, Harvey MC, Hunt RC, Tumpey AJ, Fagan RP, Schwedhelm MM, Bell S, Maher J, Kraft CS, Cagliuso NV Sr, Vanairsdale S, Vasa A, Smith PW.

Health Secur. 2017 May/Jun;15(3):253-260. doi: 10.1089/hs.2017.0005.

37.

Treating the Symptom but Not the Underlying Disease in Infective Endocarditis: A Teachable Moment.

Serota DP, Kraft CS, Weimer MB.

JAMA Intern Med. 2017 Jul 1;177(7):1026-1027. doi: 10.1001/jamainternmed.2017.1489. No abstract available.

PMID:
28505250
38.

The Residual Vaccine-preventable Burden of Rotavirus Disease.

Sederdahl BK, Yi J, Jerris R, Gillespie SE, Westblade L, Kraft CS, Shane AL, Lopman B, Anderson EJ.

Pediatr Infect Dis J. 2017 Aug;36(8):780-781. doi: 10.1097/INF.0000000000001580.

PMID:
28221240
39.

Fecal Microbiota Transplant for Clostridium difficile Infection in a Pregnant Patient.

Saeedi BJ, Morison DG, Kraft CS, Dhere T.

Obstet Gynecol. 2017 Mar;129(3):507-509. doi: 10.1097/AOG.0000000000001911.

PMID:
28178052
40.

Challenges in fecal donor selection and screening for fecal microbiota transplantation: A review.

Woodworth MH, Carpentieri C, Sitchenko KL, Kraft CS.

Gut Microbes. 2017 May 4;8(3):225-237. doi: 10.1080/19490976.2017.1286006. Epub 2017 Jan 27. Review.

41.

Diagnostic and Therapeutic Considerations for Oncology Patients With Clostridium difficile Infection.

Woodworth MH, Kraft CS.

J Oncol Pract. 2017 Jan;13(1):31-32. doi: 10.1200/JOP.2016.019141. No abstract available.

42.

Laboratory Testing of Donors and Stool Samples for Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection.

Woodworth MH, Neish EM, Miller NS, Dhere T, Burd EM, Carpentieri C, Sitchenko KL, Kraft CS.

J Clin Microbiol. 2017 Apr;55(4):1002-1010. doi: 10.1128/JCM.02327-16. Epub 2017 Jan 11. Review.

43.

Risk factors and epidemiology of Clostridium difficile infection in hematopoietic stem cell transplant recipients during the peritransplant period.

Aldrete SD, Kraft CS, Magee MJ, Chan A, Hutcherson D, Langston AA, Greenwell BI, Burd EM, Friedman-Moraco R.

Transpl Infect Dis. 2017 Feb;19(1). doi: 10.1111/tid.12649.

PMID:
27943501
44.

The rectal mucosa and condomless receptive anal intercourse in HIV-negative MSM: implications for HIV transmission and prevention.

Kelley CF, Kraft CS, de Man TJ, Duphare C, Lee HW, Yang J, Easley KA, Tharp GK, Mulligan MJ, Sullivan PS, Bosinger SE, Amara RR.

Mucosal Immunol. 2017 Jul;10(4):996-1007. doi: 10.1038/mi.2016.97. Epub 2016 Nov 16.

45.

Rotavirus and Norovirus in Pediatric Healthcare-Associated Gastroenteritis.

Yi J, Sederdahl BK, Wahl K, Jerris RR, Kraft CS, McCracken C, Gillespie S, Kirby AE, Shane AL, Moe CL, Anderson EJ.

Open Forum Infect Dis. 2016 Aug 30;3(4):ofw181. eCollection 2016 Oct.

46.

A Rose by Any Other Name: Practical Updates on Microbial Nomenclature for Clinical Microbiology.

Kraft CS, McAdam AJ, Carroll KC.

J Clin Microbiol. 2016 Dec 28;55(1):3-4. doi: 10.1128/JCM.02169-16. Print 2017 Jan. No abstract available.

47.

Editorial Commentary: Considerations of Favipiravir as a Medical Countermeasure in Future Randomized Controlled Trials Against Ebola Virus Disease.

Kraft CS.

Clin Infect Dis. 2016 Nov 15;63(10):1295-1296. Epub 2016 Aug 23. No abstract available.

PMID:
27553374
48.

Human Immunodeficiency Virus.

Armstrong WS, Guarner J, Kraft CS, Caliendo AM.

Microbiol Spectr. 2016 Aug;4(4). doi: 10.1128/microbiolspec.DMIH2-0024-2015. Review.

PMID:
27726785
49.

Overlooking the importance of immunoassays - Authors' reply.

Cnops L, van Griensven J, Honko AN, Bausch DG, Sprecher A, Hill CE, Colebunders R, Johnson JC, Griffiths A, Palacios GF, Kraft CS, Kobinger G, Hewlett A, Norwood DA, Sabeti P, Jahrling PB, Formenty P, Kuhn JH, Ariën KK.

Lancet Infect Dis. 2016 Oct;16(10):1110. doi: 10.1016/S1473-3099(16)30339-5. Epub 2016 Sep 19. No abstract available.

PMID:
27676345
50.

Long-term Management of Panuveitis and Iris Heterochromia in an Ebola Survivor.

Shantha JG, Crozier I, Varkey JB, Kraft CS, Lyon GM 3rd, Mehta AK, Carlson RD, Hill CE, Kumar G, Debiec MR, Patel PS, Olsen TW, Nussenblatt RB, Martin DF, Ströher U, Uyeki TM, Ribner BS, Smith JR, Yeh S.

Ophthalmology. 2016 Dec;123(12):2626-2628.e2. doi: 10.1016/j.ophtha.2016.07.013. Epub 2016 Sep 1. No abstract available.

Supplemental Content

Loading ...
Support Center